Imara Inc (IMRA) USD0.001
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing novel therapeutics to treat rare inherited genetic disorders of hemoglobin. The Company’s product pipeline includes IMR-687 (tovinontrine). IMR-687 is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD and beta-thalassemi. IMR-687 is a selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9), that has a multimodal mechanism of action that acts primarily on red blood cells (RBCs) and has the potential to act on white blood cells (WBCs), adhesion mediators and other cell types. PDE9 decreases cyclic guanosine monophosphate (cGMP), an active signaling molecule. The Company is conducting Phase II b clinical trials of IMR-68.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.